TY  - JOUR
AU  - Slansky, Jill E.
AU  - Harmacek, Laura D.
AU  - O’Connor, Brian P.
PY  - 2017
TI  - Epigenetic profiling of tumor infiltrating lymphocytes
JF  - Translational Cancer Research; Vol 6, Supplement 6 (August 29, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - Blocking T cell inhibitory signals, or “checkpoint blockade”, has provided unprecedented clinical results for therapy of cancer (1). Antibodies that block negative interactions between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) allow activation of T cells that recognize tumor antigens and promote immune destruction of the tumor. To determine the activities of T cells of tumor infiltrating lymphocytes (TILs), and to determine which patients will most effectively respond to checkpoint blockade therapies, Schietinger and colleagues developed a novel inducible autochthonous tumor in AST × CreERT2 mice. In this system, they successfully analyzed TIL activity and chromatin remodeling during tumor development (2,3).
UR  - https://tcr.amegroups.org/article/view/15006